A new study found that watching violent images causes different brain activity in people with and without aggressive traits. Participants with aggressive tendencies had less brain activity in the orbitofrontal cortex while watching violent movies, but increased blood pressure.
A novel polypill with a fixed-dose combination of blood thinner, cholesterol-lowering drug, and angiotensin-converting-enzyme inhibitor shows promise in increasing patient adherence to treatment following a myocardial infarction. The study found that patients were more likely to take their medication when given as a polypill compared t...
The study found that gram-positive bacteria, including staph and strep infections, accounted for 95 percent of endophthalmitis cases. The findings suggest better treatment with targeted antibiotics, but also highlight increasing resistance to certain antibiotics.
A study published in Cell Host & Microbe reveals how the Ebola virus blocks the body's first line of defense against infection. By targeting a specific protein called eVP24, the virus cripples the immune system's ability to respond effectively, allowing it to mass-produce itself and trigger a deadly response.
Researchers at Mount Sinai Hospital discovered a biomarker linked to PTSD development, centered around the glucocorticoid receptor. This receptor is found in stressed animals with PTSD and may be targeted for new treatments.
Researchers at Mount Sinai School of Medicine developed an effective treatment for the rare disorder, which causes continuous feelings of swaying or rocking. The treatment re-adapts the vestibulo-ocular reflex, a mechanism in the inner ear that maintains balance, and achieves significant recovery rates in patients.
Researchers have identified over 100 locations in the human genome associated with the risk of developing schizophrenia, pointing to genetic variations that make people vulnerable to psychiatric disease. The study's findings could lead to new approaches to treating the disorder and inform drug development for acute need.
A recent study led by researchers at the Icahn School of Medicine at Mount Sinai found that nearly 60% of autism risk is caused by inherited variant genes common in the population. Rare genetic factors, such as de novo mutations, also contribute to the disorder, but only account for a small fraction of total risk.
A study found that variations in the TANC1 gene are associated with a greater risk of radiation-driven side effects in prostate cancer patients. The research team developed a predictive genomic test to optimize treatment plans, allowing for improved quality of life for many cancer survivors.
A study found that genetic mutations in liver cells drive tumor formation in iCCA, with mutant proteins impairing liver cell development and increasing the risk of metastasis. Researchers discovered a potential treatment option by targeting IDH1/2 mutations, opening a new line of investigation for biomarkers and life-saving decisions.
A study found that Lavado cocoa extract reduces β-amyloid formation, which damages nerve cells in Alzheimer's disease. The extract also rescues synaptic function, a potential target for an effective Alzheimer's disease drug.
Researchers at the Icahn School of Medicine at Mount Sinai found that mammals do not use RNAi to fight viruses, contrary to previous studies. Instead, they use microRNAs, which are part of a different defense system based on interferons, signaling proteins made by immune cells.
Researchers at Mount Sinai Hospital discovered that a protein called Sirtuin1 (SIRT1) is essential for maintaining healthy aging of blood stem cells. The study found that loss of SIRT1 leads to impaired regeneration and resembles aged, defective stem cells in mouse models.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
Researchers at Mount Sinai Hospital have re-examined multiple sclerosis (MS) clinical course descriptions to provide a framework for both clinical research and ongoing clinical care. The proposed 2013 revisions include improved clinical descriptive terminology, MRI imaging, and analysis of fluid biomarkers.
Researchers at Mount Sinai present landmark studies on an immune response in prostate cancer tumors, effects of paternal age on live birth rates and treatment modalities for benign prostatic hyperplasia. The studies demonstrate complexities of immunotherapy and its impact on survival rates and fertility outcomes.
Researchers found high prevalence of hypertension and elevated cholesterol among HIV patients, with low rates of control. The study recommends greater emphasis on cardiology in HIV treatment and research to optimize heart disease risk factor management.
A study published in Neuron found that subtle changes in inhibitory signaling can affect how animals respond to drugs like cocaine. Researchers identified SNX27 as a promising target for treating addiction by regulating the excitability of dopamine neurons.
Researchers at the Mount Sinai Hospital identified subtle changes in inhibitory signaling in the reward pathway, affecting how animals respond to drugs like cocaine. The study highlights sorting nexin 27 as a promising target for treating addiction and may lead to new therapeutic options.
The LEADLESS study found that the leadless pacemaker demonstrated overall device performance comparable to conventional pacemakers, with no infections or failures to sense, pace, or communicate. The device's benefits may allow for less patient discomfort and device complications.
Researchers at Mount Sinai identified a new technique to expand hematopoietic stem cells in cord blood, making them more useful for adult patients. This study has important implications for patients battling blood cancers and the success of life-saving stem cell transplants.
A large family study found that genetic relatedness in families increases the risk of autism spectrum disorder, while unique environmental factors also play a significant role. The study used a population-based sample of over two million Swedish children and revealed a strong link between genetic and environmental influences.
Researchers have identified the RAF1 gene as a cause of childhood-onset dilated cardiomyopathy, a progressive and potentially fatal heart condition. The study found that patients with this genetic variant showed increased activity of the protein mTOR, which can be inhibited with FDA-approved drugs.
A study of almost 2,500 families found that genetic alterations in shared biological pathways are a significant risk factor for autism spectrum disorders (ASD). Individuals with ASD had more CNVs affecting genes involved in brain development and synapse function.
Researchers found that activating neurons instead of dampening them opens a new avenue to mimic and promote natural resilience. The study suggests a conceptually novel therapeutic strategy for treating depression.
The National Institutes of Health has awarded Mount Sinai a $26 million contract to support pandemic preparedness and advance the understanding of flu biology. Researchers will conduct animal surveillance studies, analyze virus-host interactions, and develop new vaccines.
A study published in Biological Psychiatry found that intranasal ketamine conferred an unusually rapid antidepressant effect within 24 hours and was well-tolerated in patients with treatment-resistant major depressive disorder. The results show promise for a new treatment class, targeting the NMDA glutamate receptor.
Researchers found a significant link between exposure to inhaled particulate matter at Ground Zero and the development of obstructive sleep apnea and post-traumatic stress disorder (PTSD) in first responders. The study also showed that those with PTSD had higher levels of inflammation, increasing their risk for cardiovascular disease.
A new stool-based screening test, Cologuard, detected 92% of colorectal cancer and 42% of advanced pre-cancerous lesions, outperforming a commercial occult blood fecal immunochemical test. The non-invasive test allows patients to collect samples at home, increasing the potential for higher cancer screening rates.
A Mount Sinai study reveals that GM-CSF protein production is critical for maintaining immune tolerance in the gut, and its deficiency may lead to increased susceptibility to inflammatory bowel diseases. The research suggests that targeting the GM-CSF axis could be a promising strategy for developing effective treatments for IBD.
Researchers at Mount Sinai Hospital have discovered how the Marburg virus interacts with host protein Keap1, allowing it to live longer and replicate better. This knowledge may lead to the development of targeted therapies to arrest the lethal virus.
A study led by Dr. Sergio A. Lira found that removing gut bacteria reduced polyp formation and inflammation in mice, potentially reducing colorectal cancer risk. The researchers propose a new approach to understanding the interplay between genetic mutations, gut bacteria, and inflammation.
Researchers discovered abnormal molecular signaling pathways that promote chronic kidney disease progression, targeting endothelial mitochondrial oxidative stress and glomerular filtration barrier. New therapeutic targets may prevent or reverse disease, providing hope for millions of Americans affected by kidney disease.
New research reveals that opioid use changes the activity of a specific protein needed for normal brain function, affecting both pain relief and tolerance. The study found that blocking this protein can reduce addiction-related behaviors, but increasing its activity lowers pain relief response and leads to faster morphine tolerance.
A randomized controlled trial found that cognitive behavioral therapy plus hypnosis significantly reduced fatigue in breast cancer patients during and after radiotherapy. The treatment group had less fatigue than 79% of control group patients at the end of radiotherapy, with benefits persisting for up to six months.
Using point-of-care ultrasound for suspected appendicitis in kids has been shown to reduce emergency room length of stay by 46% and avoid unnecessary CT scans. The study found no cases of appendicitis were missed, and surgeons became more comfortable using ultrasound for decision-making.
Researchers identified UHRF1 as a key driver of liver cancer in zebrafish models and human tumors, showing that high levels of UHRF1 can cause tumors to form rapidly. The study suggests that targeting UHRF1 could be an effective approach to halting cancer formation and offers new hope for treatments for hepatocellular carcinoma.
Two large-scale exome studies found a significant role for rare genetic mutations in schizophrenia, contrary to previous assumptions of few 'faulty' genes. The studies established the world's largest database on schizophrenia, providing valuable resources for biomedical research.
Researchers found that adolescent rats exposed to THC experienced molecular changes and increased motivation to self-administer heroin in their adulthood offspring, highlighting potential long-term effects of marijuana use on future generations.
A new nanotherapy breakthrough designed to deliver statin medication directly to inflamed blood vessels could potentially prevent repeat heart attacks and strokes. The technology targets inflammation in blood vessels, reducing the risk of clots and cardiovascular events.
Researchers at Mount Sinai have identified a promising new molecular mechanism for cocaine addiction, implicating the PARP-1 enzyme and Sidekick-1 gene. Chronic cocaine administration increases levels of PARP-1, leading to epigenetic changes that contribute to long-term addiction.
Researchers developed a novel sugar-based tracer contrast agent to aid in the detection of inflamed and vulnerable artery plaques. The new tracer, fluorodeoxymannose (FDM), shows promise in targeting high-risk plaques more specifically than traditional glucose-based tracers.
A new study found that vitamin E delays progression of functional decline by 19% per year, translating into a 6.2-month benefit over placebo. Vitamin E is also easy to purchase and inexpensive, making it a potential treatment strategy for mild-to-moderate Alzheimer's disease.
The Icahn School of Medicine at Mount Sinai is part of a new NIH Stroke Research Network aiming to expedite stroke clinical trials and build expertise in stroke prevention, treatment, and rehabilitation. The school will receive a $1.3 million grant to develop a collaborative research infrastructure.
The grant aims to build a more precise understanding of chronic traumatic encephalopathy and traumatic brain injury in civilians over age 45. Investigators will use extensive resources from an ongoing study of brain aging and conduct analyses of neuropsychology, neuroradiology, neurological, geriatric, and epidemiological aspects.
Mount Sinai researchers found that a drug-resistant H7N9 virus retained its ability to replicate and cause severe illness in humans, even after becoming resistant to Tamiflu. The study suggests that flu viruses can develop drug-resistant mutations without suffering a penalty in terms of their fitness.
New research shows microRNA-128 controls complex functions in the adult brain by adjusting a neuronal signaling pathway. Reducing miR-128 expression led to increased motor activity and fatal epilepsy in mice, while overexpression decreased motor activity and reduced seizure susceptibility.
A new classification system called MOGE(S) has been developed to classify cardiomyopathies, a group of diseases affecting the heart muscle. The system uses a descriptive nomenclature with letters to explain individual patients' cardiomyopathy types and genetic mutations.
A Mount Sinai study found that age-related cognitive decline is linked to energy in synapses in the prefrontal cortex. Estrogen treatment restored synaptic health and improved working memory in rhesus monkeys.
Researchers at the Icahn School of Medicine at Mount Sinai will investigate a new intravenous medication that blocks IL-22, a protein triggering chronic inflammation and epidermal growth abnormalities in eczema. The study aims to develop safer treatments for patients with moderate to severe AD.